NASDAQ : AKTX
Akari Therapeutics, Plc — Key statistics
Healthcare · Biotechnology · United States
Last price 8.24 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 18.83M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 18.83M |
| Enterprise Value | 11.83M |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 12, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | n/a |
| Shares Outstanding | 2.29M |
| Shares Change (YoY) | +128.91% |
| Shares Change (QoQ) | +20.68% |
| Owned by Insiders (%) | 26.30% |
| Owned by Institutions (%) | 185.54% |
| Float | 1.67M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 0.78 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 0.60 |
| Quick Ratio | 0.55 |
| Debt / Equity | 0.04 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -13.89 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -140.09% |
| Return on Assets (ROA) | -19.10% |
| Return on Invested Capital (ROIC) | -36.82% |
| Return on Capital Employed (ROCE) | -55.41% |
| Weighted Average Cost of Capital (WACC) | 15.73% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$5.16M |
| Employee Count | 6 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | -1.86M |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 1.47 |
| 52-Week Price Change | -72.55% |
| 50-Day Moving Average | 9.28 |
| 200-Day Moving Average | 9.06 |
| Relative Strength Index (RSI) | 46.96 |
| Average Volume (20 Days) | 45,735 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 17,539 |
| Short Previous Month | 14,529 |
| Short % of Shares Out | 1.38% |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 0.34 |
Incomestatement
| Measure | Value |
|---|
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -13.68M |
| Pretax Income | -32.82M |
| Net Income | -30.96M |
| EBITDA | n/a |
| EBIT | -13.68M |
| Earnings Per Share (EPS) | -$23.94 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 7.69M |
| Total Debt | 693,000 |
| Net Cash | 7.00M |
| Net Cash Per Share | $3.06 |
| Equity (Book Value) | 18.60M |
| Book Value Per Share | 10.62 |
| Working Capital | -5.61M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -10.76M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | n/a |
| Net Borrowing | 1.44M |
| Free Cash Flow | -10.76M |
| FCF Per Share | -$4.71 |
Margins
| Measure | Value |
|---|
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -128.91% |
| Shareholder Yield | -128.91% |
| Earnings Yield | -290.52% |
| FCF Yield | -57.14% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $25.50 |
| Price Target Difference | 209.47% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 3 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | Mar 31, 2026 |
| Split Type | Reverse |
| Split Ratio | 1:40 |
Scores
| Measure | Value |
|---|
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |